RxDoctor Payments Data

Stacey Miller, MD

Pulmonary Disease · Madisonville, KYNPI 1124208442

Payments from drug & device makers

$9,692in general payments, 2019–2025

Across 447 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$941
  • Boehringer Ingelheim$872
  • Johnson & Johnson$858
  • AstraZeneca$721
  • Regeneron Healthcare Solutions, Inc.$707
  • Sanofi$574
  • plus $5K from 39 others

What the payments were for

  • Travel & lodging$4935%
  • Food & beverage$9,13194%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,692 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$116,726
Medicare patients
424
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$85,856
Breztri AerosphereBudesonide/Glycopyr/Formoterol103$75,567
Stiolto RespimatTiotropium Br/Olodaterol Hcl67$37,000
Breo ElliptaFluticasone/Vilanterol53$23,308
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$21,744
Spiriva RespimatTiotropium Bromide24$18,293
Advair HfaFluticasone Propion/Salmeterol31$12,536
Bevespi AerosphereGlycopyrrolate/Formoterol Fum25$11,761
SymbicortBudesonide/Formoterol Fumarate39$11,174
Arnuity ElliptaFluticasone Furoate48$9,181
Albuterol Sulfate HfaAlbuterol Sulfate273$8,606
Incruse ElliptaUmeclidinium Bromide24$7,373
BreynaBudesonide/Formoterol Fumarate14$2,211
Ventolin HfaAlbuterol Sulfate26$1,542
Wixela InhubFluticasone Propion/Salmeterol12$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$941$147,462286 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$721$98,502167 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$872$55,29491 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Madisonville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →